panitumumab
- Generic Name
- panitumumab
- Brand Names
- Vectibix
- Drug Type
- Biotech
- CAS Number
- 339177-26-3
- Unique Ingredient Identifier
- 6A901E312A
- Background
Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent.
Panitumumab was granted FDA approval on 27 September 2006.
- Indication
美国FDA批准：用于野生型KRAS(外显子2)转移性结直肠癌(mCRC)患者的一线治疗。
- Associated Conditions
- Metastatic Colorectal Cancer (CRC)
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2025-02-11
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 390
- Registration Number
- NCT06820463
- Locations
- 🇮🇱
Hadassah Medical Center-Hebrew University /ID# 268007, Jerusalem, Israel
🇮🇱Rabin Medical Center /ID# 268008, Petah Tikva, Israel
🇺🇸Yale New Haven Hospital /ID# 270565, New Haven, Connecticut, United States
Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer
- Conditions
- HNSCCHNSCC,Larynx, Pharynx and Oral Cavity
- Interventions
- First Posted Date
- 2025-02-11
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT06819228
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/revert Resistance in Colorectal Cancer
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- First Posted Date
- 2024-12-03
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 130
- Registration Number
- NCT06714357
- Locations
- 🇮🇹
AORN Sant'Anna e San Sebastiano, Caserta, CE, Italy
🇮🇹Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy
Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer
- Conditions
- Colorectal Cancer Stage IV
- Interventions
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 500
- Registration Number
- NCT06509126
- Locations
- 🇮🇹
Istituto Nazionale Tumori di Napoli - IRCCS - Fondazione G. Pascale, Napoli, Italy
The Sagittarius Trial
- Conditions
- Colon Cancer Stage IIColon Cancer Stage III
- Interventions
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- IFOM ETS - The AIRC Institute of Molecular Oncology
- Target Recruit Count
- 700
- Registration Number
- NCT06490536
- Locations
- 🇮🇹
Istituto Clinico Humanitas, Rozzano, Milano, Italy
🇮🇹Istituto di Candiolo, Candiolo, Torino, Italy
🇮🇹Azienda Sanitaria Locale di Biella, Biella, Italy
Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- Procedure: 166Holmium TARE
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 46
- Registration Number
- NCT06332079
- Locations
- 🇮🇹
Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
Dynamic Changes in Circulating Tumour Cells Protein Expression
- First Posted Date
- 2024-03-18
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Matteo's Friends
- Target Recruit Count
- 150
- Registration Number
- NCT06314997
- Locations
- 🇮🇹
Natalia Malara, Germaneto, Italy
Botensilimab and Balstilimab Optimization in Colorectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Nicholas DeVito, MD
- Target Recruit Count
- 15
- Registration Number
- NCT06268015
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 450
- Registration Number
- NCT06252649
- Locations
- 🇺🇸
Ironwood Cancer and Research Centers Scottsdale, Chandler, Arizona, United States
🇺🇸Providence Saint Jude Medical Center, Fullerton, California, United States
🇺🇸Cancer and Blood Specialty Clinic, Los Alamitos, California, United States
Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer
- Conditions
- Metastatic Colorectal CancerMetastatic Gastroesophageal AdenocarcinomaDPD Deficiency
- Interventions
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 73
- Registration Number
- NCT06245356
- Locations
- 🇫🇷
Institut du Cancer d'Avignon, Avignon, France
🇫🇷CHU Jean Minjoz, Besançon, France
🇫🇷Centre Hospitalier de Cholet, Cholet, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.